Literature DB >> 28159712

Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics.

Erica L Clinkenbeard1, Kenneth E White2.   

Abstract

Phosphate is critical for many cellular processes and structural functions, including as a key molecule for nucleic acid synthesis and energy metabolism, as well as hydroxyapatite formation in bone. Therefore it is critical to maintain tight regulation of systemic phosphate levels. Based upon its broad biological importance, disruption of normal phosphate homeostasis has detrimental effects on skeletal integrity and overall health. Investigating heritable diseases of altered phosphate metabolism has led to key discoveries underlying the regulation and systemic actions of the phosphaturic hormone Fibroblast growth factor-23 (FGF23). Both molecular and clinical studies have revealed novel targets for the development and optimization of therapies for disorders of phosphate handling. This review will focus upon the bridge between genetic discoveries involving disorders of altered FGF23 bioactivity, as well as describe how these findings have translated into pharmacologic application.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FGF-23; Genetics; Hyperphosphatemia; Hypophosphatemia; Klotho; Tumoral calcinosis

Mesh:

Substances:

Year:  2017        PMID: 28159712      PMCID: PMC5537045          DOI: 10.1016/j.bone.2017.01.034

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  93 in total

1.  Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system.

Authors:  Hiroshi Tsujikawa; Yoko Kurotaki; Toshihiko Fujimori; Kazuhiko Fukuda; Yo-Ichi Nabeshima
Journal:  Mol Endocrinol       Date:  2003-10-03

2.  A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis.

Authors:  Tobias Larsson; Xijie Yu; Siobhan I Davis; Mohamad S Draman; Sean D Mooney; Michael J Cullen; Kenneth E White
Journal:  J Clin Endocrinol Metab       Date:  2005-02-01       Impact factor: 5.958

3.  Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder.

Authors:  M J Econs; P T McEnery
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

4.  Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.

Authors:  Yaacov Frishberg; Nobuaki Ito; Choni Rinat; Yuji Yamazaki; Sofia Feinstein; Itaru Urakawa; Paulina Navon-Elkan; Rachel Becker-Cohen; Takeyoshi Yamashita; Kaori Araya; Takashi Igarashi; Toshiro Fujita; Seiji Fukumoto
Journal:  J Bone Miner Res       Date:  2007-02       Impact factor: 6.741

5.  Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice.

Authors:  L Beck; Y Soumounou; J Martel; G Krishnamurthy; C Gauthier; C G Goodyer; H S Tenenhouse
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

6.  Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23.

Authors:  Erik A Imel; Xiaoping Zhang; Mary D Ruppe; Thomas J Weber; Mark A Klausner; Takahiro Ito; Maria Vergeire; Jeffrey S Humphrey; Francis H Glorieux; Anthony A Portale; Karl Insogna; Munro Peacock; Thomas O Carpenter
Journal:  J Clin Endocrinol Metab       Date:  2015-04-28       Impact factor: 5.958

7.  Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice.

Authors:  Erica L Clinkenbeard; Emily G Farrow; Lelia J Summers; Taryn A Cass; Jessica L Roberts; Christine A Bayt; Tim Lahm; Marjorie Albrecht; Matthew R Allen; Munro Peacock; Kenneth E White
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741

8.  The renal Na+/phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone.

Authors:  D Bacic; M Lehir; J Biber; B Kaissling; H Murer; C A Wagner
Journal:  Kidney Int       Date:  2006-02       Impact factor: 10.612

9.  A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome.

Authors:  Hannes Olauson; Tijana Krajisnik; Charlotta Larsson; Bengt Lindberg; Tobias E Larsson
Journal:  Eur J Endocrinol       Date:  2008-03-05       Impact factor: 6.664

10.  The biological function of DMP-1 in osteocyte maturation is mediated by its 57-kDa C-terminal fragment.

Authors:  Yongbo Lu; Baozhi Yuan; Chunlin Qin; Zhengguo Cao; Yixia Xie; Sarah L Dallas; Marc D McKee; Marc K Drezner; Lynda F Bonewald; Jian Q Feng
Journal:  J Bone Miner Res       Date:  2011-02       Impact factor: 6.741

View more
  6 in total

Review 1.  Renal phosphate handling and inherited disorders of phosphate reabsorption: an update.

Authors:  Carsten A Wagner; Isabel Rubio-Aliaga; Nati Hernando
Journal:  Pediatr Nephrol       Date:  2017-12-23       Impact factor: 3.714

2.  Parathyroid hormone initiates dynamic NHERF1 phosphorylation cycling and conformational changes that regulate NPT2A-dependent phosphate transport.

Authors:  Qiangmin Zhang; Kunhong Xiao; José M Paredes; Tatyana Mamonova; W Bruce Sneddon; Hongda Liu; Dawei Wang; Sheng Li; Jennifer C McGarvey; David Uehling; Rima Al-Awar; Babu Joseph; Frederic Jean-Alphonse; Angel Orte; Peter A Friedman
Journal:  J Biol Chem       Date:  2019-01-29       Impact factor: 5.157

Review 3.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

4.  Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men.

Authors:  Arezoo Daryadel; Carla Bettoni; Thomas Haider; Pedro H Imenez Silva; Udo Schnitzbauer; Eva Maria Pastor-Arroyo; Roland H Wenger; Max Gassmann; Carsten A Wagner
Journal:  Pflugers Arch       Date:  2018-07-02       Impact factor: 3.657

Review 5.  FGF23 signalling and physiology.

Authors:  Bryan B Ho; Clemens Bergwitz
Journal:  J Mol Endocrinol       Date:  2021-02       Impact factor: 5.098

6.  Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23.

Authors:  Patrick L Mulcrone; Shanique K E Edwards; Daniela N Petrusca; Laura S Haneline; Jesús Delgado-Calle; G David Roodman
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.